SCHEMBL23728243

SCHEMBL23728243

C[C]=C(C)c1ccc(O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.48
ESR2 Q92731 6/20 0.48
CYP19A1 P11511 1/20 0.45
HSD17B1 P14061 1/20 0.44
MAPT P10636 5/20 0.44
HSD17B10 Q99714 5/20 0.44
LMNA P02545 5/20 0.44
CYP3A4 P08684 4/20 0.44
ALOX15 P16050 4/20 0.44
HIF1A Q16665 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
NR3C1 P04150 2/20 0.44
TP53 P04637 2/20 0.44
CYP1A2 P05177 2/20 0.44
ADORA3 P0DMS8 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
OPRD1 P41143 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23728241 1.00 ESR1 (0.48) ESR1ESR2CYP19A1HSD17B1MAPT
SCHEMBL6534931 0.77 CES2 (0.44) MAPTLMNACYP3A4ALOX15MEN1
SCHEMBL12261146 0.77 ESR1 (0.46) ESR1ESR2CYP19A1HSD17B1MAPT
SCHEMBL701017 0.76 CES2 (0.44) ESR1MAPTHSD17B10LMNACYP3A4
SCHEMBL3846147 0.76 CES2 (0.44) ESR1MAPTHSD17B10LMNACYP3A4
SCHEMBL9194201 0.76 CES2 (0.44) ESR1MAPTHSD17B10LMNACYP3A4
SCHEMBL1071921 0.71 ESR1 (0.57) ESR1ESR2CYP19A1HSD17B1MAPT
Dimethylstilbestrol SCHEMBL125635 0.71 ESR1 (0.74) ESR1ESR2CYP19A1HSD17B1MAPT
Dimethylstilbestrol SCHEMBL13339102 0.71 ESR1 (0.74) ESR1ESR2CYP19A1HSD17B1MAPT
SCHEMBL3656765 0.71 ESR1 (0.57) ESR1ESR2CYP19A1HSD17B1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB ESR1 1524/4885ESR2 409/4885CYP19A1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.